Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML
Asciminib Could Be New Option For Resistant Patients
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
You may also be interested in...
US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.